Results 291 to 300 of about 326,057 (302)

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Blood, 2013
Simona Soverini, Caterina De Benedittis, Gabriele Gugliotta   +2 more
exaly  

<p>Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies</p>

OncoTargets and Therapy, 2019
Tracy L Putoczki, Stanley S Stylli, Rodney B Luwor   +2 more
exaly  

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

Journal of Thoracic Oncology, 2015
Chao-Hua Chiu, Cheng-Ta Yang, Jin-Yuan Shih   +2 more
exaly  

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

Lung Cancer, 2013
Hua-Jun Chen, Zhen Wang, Bin-Chao Wang   +2 more
exaly  

Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells

Angewandte Chemie - International Edition, 2018
Karim Aljakouch, Tatjana Lechtonen, Hesham K Yosef   +2 more
exaly  

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

Lancet, The, 2002
Wolf-Karsten Hofmann, Sven De Vos, David Elashoff   +2 more
exaly  

Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor

Pharmacotherapy, 2018
Jordan N Markowitz, Karen M Fancher
exaly  

TYROSINE KINASE INHIBITORS

2002
openaire   +1 more source

Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma

Annals of Oncology, 2016
M H Voss, A Viudez, D F Mcdermott
exaly  

Tyrosine Kinase Inhibitor

2013
openaire   +1 more source